The abstract is read at the publisher; the summary is JClub's.
In adults with lung or kidney transplant, two doses of AS01(E)-adjuvanted RSVPreF3 increased RSV-A and RSV-B neutralizing titers after dose 2 by 1.34 and 1.26, respectively.
- Why it matters: Immunocompromised transplant recipients face higher risk of severe RSV, but vaccine immunogenicity and safety in this group need clearer evidence over time.
- What they did: In a multicountry open-label phase 2b trial (NCT05921903), transplant recipients ≥18 were randomized 1:1 to one dose (n = 131) or two doses 30–60 days apart (n = 130), with a control of non-immunocompromised adults ≥50 receiving one dose (n = 125).
- The result: Two-dose recipients showed numerically higher neutralizing titers one month post-dose 2 than post-dose 1, while a single dose was immunogenic but had slower, generally lower early responses than controls, especially with mycophenolate; immune responses stayed above baseline for 12 months and both dosing regimens were well tolerated.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.